Meningococcal Conjugate Vaccines Policy Update: Booster Dose Recommendations
暂无分享,去创建一个
Lucia H. Lee | C. Byington | J. Swanson | K. Edwards | Y. Maldonado | B. Gellin | M. Fischer | M. Brady | J. Seward | M. Jackson | W. Orenstein | H. Bernstein | H. Keyserling | D. Kimberlin | R. Bortolussi | M. Fisher | M. Glodé | G. Schutze | R. Willoughby | R. Gorman | R. D. Pratt | J. Starke | T. Tan
[1] E. Zell,et al. Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine , 2011, The Pediatric infectious disease journal.
[2] S. Humiston,et al. Patient—Provider Communication and Human Papillomavirus Vaccine Acceptance , 2011, Clinical pediatrics.
[3] K. Reisinger,et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. , 2010, Vaccine.
[4] C. Gill,et al. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents , 2010, Human vaccines.
[5] Ly-Mee Yu,et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Paige L. Williams,et al. Phase I/II, Open-Label Trial of Safety and Immunogenicity of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Human Immunodeficiency Virus-Infected Adolescents , 2010, The Pediatric infectious disease journal.
[7] N. Andrews,et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. , 2006, The Journal of infectious diseases.
[8] D. Kelly,et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] D. Granoff,et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. , 2006, The Journal of infectious diseases.
[10] S. Long,et al. Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients , 2005, Pediatrics.
[11] Oleg O. Bilukha,et al. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[12] D. Kelly,et al. Lack of Serum Bactericidal Activity in Preschool Children Two Years After a Single Dose of Serogroup C Meningococcal Polysaccharide-Protein Conjugate Vaccine , 2005, The Pediatric infectious disease journal.
[13] N. Andrews,et al. Immune Response to Meningococcal Serogroup C Conjugate Vaccine in Asplenic Individuals , 2004, Infection and Immunity.
[14] H. Käyhty,et al. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. , 2003, Vaccine.
[15] M. Daha,et al. Protection against meningococcal serogroup ACYW disease in complement‐deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine , 1998, Clinical and experimental immunology.
[16] S. Dowell,et al. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases. , 1996, Pediatrics.
[17] R. Jacobs,et al. Meningococcal disease prevention and control strategies for practice-based physicians. Committee on Infectious Diseases, American Academy of Pediatrics. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. , 1996, Pediatrics.
[18] Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. , 2011, MMWR. Morbidity and mortality weekly report.
[19] Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. , 2009, MMWR. Morbidity and mortality weekly report.